About Sarika Singh
Sarika Singh Ph.D. combines a deep technical background in chemistry with more than a decade of legal practice. Her career moves between laboratories and law offices, and the pattern shows an emphasis on intellectual property matters that touch both disciplines.
She earned a Ph.D. in Synthetic Organic Chemistry from the University of Delhi in 1993. More than a decade later she completed a J.D. at Rutgers School of Law–Newark in 2006. Those two degrees frame a career that spans bench science, patent science and later, courtroom-side legal work.
Her industry career began at Ranbaxy Laboratories Ltd. in 2000, where she served as a group leader and research scientist in intellectual property. She advanced to Senior Patent Scientist at Ranbaxy Europe Ltd. in 2004 and is listed as Director–Global IP at Ranbaxy Inc., USA in 2006. Those roles involved scientific assessment of pharmaceutical inventions and work on patent-related matters within an industrial research context.
By 2009 she had moved into law practice roles. She worked as a lawyer and law clerk at McNeely & Hare LLP in 2009, then as an associate at McDermott, Will & Emery beginning in 2011. In 2015 she returned to McNeely Hare & War LLP as counsel. She is licensed to practice in both New York and New Jersey.
Singh’s background gives her a practical understanding of patent prosecution and portfolio decisions for chemical and pharmaceutical innovations. She has experience assessing patentability, advising on patent strategy and coordinating between scientific teams and outside counsel. Her scientific training informs technical claim drafting and prior art analysis, while her legal experience guides enforcement and transactional considerations.
Outside of firm work she is a member of the American Chemical Society, which connects her to continuing developments in chemical research and professional networks in the sciences.
She works from an office at McNeely Hare & War LLP. Her current practice centers on patent and intellectual property matters affecting chemical and pharmaceutical technologies in New York and New Jersey.
